AU2007230991A1 - Compounds and methods for treatment of disorders associated with ER stress - Google Patents

Compounds and methods for treatment of disorders associated with ER stress Download PDF

Info

Publication number
AU2007230991A1
AU2007230991A1 AU2007230991A AU2007230991A AU2007230991A1 AU 2007230991 A1 AU2007230991 A1 AU 2007230991A1 AU 2007230991 A AU2007230991 A AU 2007230991A AU 2007230991 A AU2007230991 A AU 2007230991A AU 2007230991 A1 AU2007230991 A1 AU 2007230991A1
Authority
AU
Australia
Prior art keywords
independently
lower alkyl
substituted
occurrence
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007230991A
Other languages
English (en)
Inventor
Nicholas D.P. Cosford
Teoman Uysal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SYNDEXA PHARMACEUTICALS CORP
Original Assignee
SYNDEXA PHARMACEUTICALS CORP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SYNDEXA PHARMACEUTICALS CORP filed Critical SYNDEXA PHARMACEUTICALS CORP
Publication of AU2007230991A1 publication Critical patent/AU2007230991A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2007230991A 2006-03-22 2007-03-22 Compounds and methods for treatment of disorders associated with ER stress Abandoned AU2007230991A1 (en)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US78533506P 2006-03-22 2006-03-22
US78518206P 2006-03-22 2006-03-22
US78503506P 2006-03-22 2006-03-22
US78523506P 2006-03-22 2006-03-22
US78503406P 2006-03-22 2006-03-22
US78518506P 2006-03-22 2006-03-22
US78500706P 2006-03-22 2006-03-22
US78515406P 2006-03-22 2006-03-22
US78533806P 2006-03-22 2006-03-22
US78532806P 2006-03-22 2006-03-22
US60/785,335 2006-03-22
US60/785,185 2006-03-22
US60/785,154 2006-03-22
US60/785,235 2006-03-22
US60/785,182 2006-03-22
US60/785,338 2006-03-22
US60/785,007 2006-03-22
US60/785,035 2006-03-22
US60/785,034 2006-03-22
US60/785,328 2006-03-22
PCT/US2007/007228 WO2007111994A2 (en) 2006-03-22 2007-03-22 Compounds and methods for treatment of disorders associated with er stress

Publications (1)

Publication Number Publication Date
AU2007230991A1 true AU2007230991A1 (en) 2007-10-04

Family

ID=38541676

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007230991A Abandoned AU2007230991A1 (en) 2006-03-22 2007-03-22 Compounds and methods for treatment of disorders associated with ER stress

Country Status (6)

Country Link
US (1) US20090131384A1 (enExample)
EP (1) EP2001897A2 (enExample)
JP (1) JP2009530399A (enExample)
AU (1) AU2007230991A1 (enExample)
CA (1) CA2681639A1 (enExample)
WO (1) WO2007111994A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8090120B2 (en) 2004-10-26 2012-01-03 Dolby Laboratories Licensing Corporation Calculating and adjusting the perceived loudness and/or the perceived spectral balance of an audio signal
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US20110092554A1 (en) * 2007-11-19 2011-04-21 Richard Chesworth 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
NZ595035A (en) 2007-11-27 2012-11-30 Ardea Biosciences Inc Substituted diazole and triazole compounds and compositions and methods of use
KR20100135711A (ko) 2007-12-20 2010-12-27 엔비보 파마슈티칼즈, 인코퍼레이티드 사중치환된 벤젠
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US9340569B2 (en) * 2008-11-03 2016-05-17 Tufts University Methods and compositions for inhibiting clostridium difficile spore germination and outgrowth
EP2255813A1 (en) * 2009-05-29 2010-12-01 The Royal College of Surgeons in Ireland Derivatives of ursodeoxycholic acid for the treatment of diarrhoea
MX2012007759A (es) 2009-12-29 2012-08-01 Mapi Pharma Ltd Compuestos intermedios y procesos para la preparacion de tapentadol y compuestos relacionados.
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
MX342288B (es) 2010-04-22 2016-09-23 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
WO2011159840A2 (en) 2010-06-16 2011-12-22 Ardea Biosciences, Inc. Phenylthioacetate compounds, compositions and methods of use
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2776028B1 (en) 2011-11-03 2018-10-17 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
EP2844257A4 (en) 2012-05-01 2016-06-01 Catabasis Pharmaceuticals Inc Fatty Acid Conjugates from Statin and FXR Agonists; COMPOSITIONS AND METHODS OF USE
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
CN104822374A (zh) 2012-09-27 2015-08-05 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
US9475749B2 (en) 2013-03-14 2016-10-25 University Of Macau Anti-neurodegenerative natural compound isolated from alpiniae oxyphyllae fructose and their total synthesis
KR102447581B1 (ko) 2014-04-15 2022-09-28 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막전도 조절자 매개 질환 치료용 약제학적 조성물
CA2966885A1 (en) * 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
KR20170099909A (ko) 2014-11-26 2017-09-01 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
HK1245100A1 (zh) 2015-02-11 2018-08-24 Enanta Pharmaceuticals, Inc. 作为fxr/tgr5激动剂的胆汁酸类似物及其使用方法
NZ735126A (en) 2015-03-31 2022-10-28 Enanta Pharm Inc Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
DE102017005884A1 (de) 2016-07-07 2018-01-11 Merck Patent Gmbh Elektronisches Schaltelement
AU2017368069B2 (en) 2016-11-29 2021-07-08 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
JP7136802B2 (ja) 2017-04-07 2022-09-13 エナンタ ファーマシューティカルズ インコーポレイテッド スルホニルカルバマート胆汁酸誘導体の調製のためのプロセス
DE102018004733A1 (de) * 2018-06-14 2019-12-19 Merck Patent Gmbh Verfahren zur Herstellung eines elektronischen Bauteils enthaltend eine selbstorganisierte Monolage
CN116925168A (zh) * 2019-08-23 2023-10-24 深圳云合医药科技合伙企业(有限合伙) 胆汁酸衍生物及其组合物和应用
JP2024529444A (ja) * 2021-07-26 2024-08-06 シャペロン インク. TNF-α生成及び炎症複合体活性抑制新規化合物及びその製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1152801B (it) * 1982-08-17 1987-01-14 Proter Spa Composti steroidei ad attivita' coleretica, processo per la loro preparazione e composizioni terapeutiche che li contengono come principio attivo
JPS60161996A (ja) * 1984-02-01 1985-08-23 Eisai Co Ltd ケノデオキシコ−ル酸またはウルソデオキシコ−ル酸誘導体およびその製造法ならびにそれを含有する医薬
JP2616845B2 (ja) * 1991-02-21 1997-06-04 清水化学株式会社 システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
JPH0959162A (ja) * 1995-08-28 1997-03-04 Makoto Takahashi 胆石溶解剤
CA2405151A1 (en) * 2000-04-07 2001-10-18 University Of Maryland, Baltimore Bile acid containing prodrugs with enhanced bioavailability
US6900192B2 (en) * 2000-10-06 2005-05-31 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs

Also Published As

Publication number Publication date
US20090131384A1 (en) 2009-05-21
EP2001897A2 (en) 2008-12-17
WO2007111994A3 (en) 2008-06-12
WO2007111994A2 (en) 2007-10-04
JP2009530399A (ja) 2009-08-27
CA2681639A1 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
AU2007230991A1 (en) Compounds and methods for treatment of disorders associated with ER stress
EP2094673B1 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
US9572784B2 (en) Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CN103096895B (zh) 烟酸模拟物及其使用的方法
DK2041068T3 (en) POSITIVELY CHARGED, WATER SOLUBLE PRODRUGS OF IBUPROFEN WITH VERY FAST SKIN PENETRATION SPEED
TW201711706A (zh) 標靶藥物遞送及提升siRNA活性用脂溶性維生素化合物
JP6608404B2 (ja) 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の処置方法
CN104780915A (zh) 包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物
TW201805283A (zh) sGC刺激劑之固體形式
TW201336831A (zh) 作為鈣感測受體調節劑之取代二氫苯並哌喃化合物
JP5341521B2 (ja) タンパク質と結合パートナーとの相互作用を阻害するための化合物及び方法
US20250313522A1 (en) Phenoxy carboxylic acid compounds and medical uses thereof
CN118620018B (zh) 一种侧链含噁二唑结构的甾体类fxr激动剂及其制备方法和应用
CN104583162A (zh) 治疗中度至重度疼痛的组合物和方法
JP2024041865A (ja) パ-キンソン病治療用の新規高透過薬物及びその組成物
US11958869B2 (en) Ruthenium arene Schiff-base complexes and uses thereof
CN104797568A (zh) 用于治疗神经障碍的组合物和方法
CN102432607A (zh) 一种吡嗪异喹啉衍生物在制备治疗血吸虫药物中的应用
CN102532114A (zh) 烟酸衍生物,其制备方法及其药物组合物
CN113402444A (zh) 一种咔唑类化合物及其在制备治疗脂肪肝及2型糖尿病等代谢相关疾病药物中的应用
WO2013070911A1 (en) Compounds and methods for treating cystic fibrosis
WO2012049566A1 (en) Combination therapy for use in treating diabetes
WO2014151697A1 (en) Therapeutic uses for geranylgeranyl acetone and derivatives thereof
WO2025096684A1 (en) Err modulators
CN116925049A (zh) 新型联苯类衍生物、其制备方法及其作为药物的用途

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application